Ayala Pharmaceuticals reports promising data from Desmoid Tumors trial 19-Oct-2022 Updated interim results from Part A the RINGSIDE pivotal Phase 2/3 study of the company’s AL102 new drug showed consistent early tumor shrinkage with measures deepening over time, plus good tolerability at all doses.